Add
AMBS to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| AMBS > SEC Filings for AMBS > Form 8-K on 11-Feb-2013 | All Recent SEC Filings |
11-Feb-2013
Other Events, Financial Statements and Exhibits
On 8 February 2013, the Board of Directors of Amarantus Bioscience, Inc. finding that it would be beneficial for the Company to form a subsidiary and license the Company's diagnostic Intellectual Property to the subsidiary, approved a Resolution directing Amarantus' officers to take any all steps necessary dto form the subsidiary and license the Company's diagnostic IP to it, including the LymPro Alzheimer's disease blood test, and the NuroPro Diagnostic Platform, including the NuroPro Parkinson's disease blood test.
The name of the new diagnostic subsidiary will be Amarantus Diagnostics, Inc. The Company's current President and CEO, Gerald Commissiong, will be the initial sole Director and interim CEO of the diagnostics subsidiary and the Company's CFO, Marc Faeber, will be the interim CFO. Amarantus Diagnostics, Inc's lead asset will be the LymPro Alzheimer's disease blood test.
A copy of the Unanimous Consent of the Board of Directors adopting the resolution to form Amarantus Diagnostics, Inc. is attached as Exhibit 99.1 to this Form.
(d) Exhibits.
Exhibit No.
99.1 Unanimous Consent of the Board of Directos of Amarantus Bioscience, Inc. adopting the resolution to form a subsidiary: Amarantus Diagnostics, Inc.
|
|